Abstract
Selective glucocorticoid agonists represent a major class of anti-inflammatory agents and selective glucocorticoid antagonists show potential for significant therapeutic utility. The identification of a novel heterocyclic pharmacophore (the 2,5-dihydro-1H-[1]benzopyrano[3,4-f]- quinoline ring system) provides high affinity, selective, glucocorticoid ligands that could lead to the development of major new drugs.